Universal-Beteiligungs- und Servicegesellschaft
MLTX icon

Universal-Beteiligungs- und Servicegesellschaft’s MoonLake Immunotherapeutics MLTX Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,790
Closed -$604K – 2139
2025
Q2 		$604K Sell
12,790
-2,000
-14% -$81.5K ﹤0.01% 1638
2025
Q1 		$578K Sell
14,790
-5,351
-27% -$231K ﹤0.01% 1613
2024
Q4 		$1.09M Buy
+20,141
New +$1.03M ﹤0.01% 937

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's MLTX Position: Q3 2025 in Review

Universal-Beteiligungs- und Servicegesellschaft sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 12,790 shares — an estimated $604K sold.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in MLTX in Q4 2024 and held it in 3 quarters. The position peaked at $1.09M in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Universal-Beteiligungs- und Servicegesellschaft reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Universal-Beteiligungs- und Servicegesellschaft sold 12,790 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $604K.
  • Universal-Beteiligungs- und Servicegesellschaft first reported a position in MoonLake Immunotherapeutics in Q4 2024 and held it in 3 quarters.
  • Universal-Beteiligungs- und Servicegesellschaft's MoonLake Immunotherapeutics position peaked at $1.09M in Q4 2024.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q3 2025, filed 30 Oct 2025.